What Pemgarda treats
Pemgarda (pemivibart) is a monoclonal antibody therapy authorized for the prevention of COVID-19 in individuals who are moderately to severely immunocompromised and may not mount an adequate response to COVID-19 vaccination. It offers passive immunity by directly providing virus-neutralizing antibodies, helping to reduce the risk of symptomatic infection in high-risk patients.
Benefits of Pemgarda
Patients receiving Pemgarda may benefit from:
- Immediate passive protection against COVID-19
- Reduced risk of symptomatic COVID-19 infection
- Added security in high-risk environments for those with weakened immune systems
Pemgarda helps fill a critical gap in protection for patients who remain vulnerable despite vaccination.
Possible Side Effects of Pemgarda
Pemgarda is generally well-tolerated. Common side effects may include:
- Headache
- Fatigue
- Nausea
- Mild infusion-related reactions
Serious but rare risks may include:
- Hypersensitivity or allergic reactions
- Anaphylaxis (infusions are administered under medical supervision)
Patients are observed during and after infusion to ensure safety.
How infusion works at Prime
Pemgarda is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Pemgarda, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Pemgarda Work?
Pemgarda works by binding to the spike protein of the SARS-CoV-2 virus, blocking the virus from attaching to and entering human cells. Unlike vaccines, which stimulate the immune system to create antibodies over time, Pemgarda delivers lab-engineered antibodies that offer immediate protection. It is administered as a single intravenous infusion, providing protection for a defined duration, typically several months.
Who is Pemgarda For?
Pemgarda is intended for individuals who:
- Are moderately to severely immunocompromised (e.g., transplant recipients, patients undergoing cancer treatment, those with primary immunodeficiencies)
- Are unlikely to respond adequately to COVID-19 vaccination
- Are at high risk for severe outcomes if infected with COVID-19
It is not a substitute for vaccination but may be used alongside other preventive measures in vulnerable patients.